Impact of KRAS mutation status on outcomes of metastatic colorectal cancer treated with anti-angiogenic agents: a meta-analysis.

作者: Xiaojun Liang , Jie Shen

DOI: 10.1080/1120009X.2019.1692282

关键词:

摘要: The impact of KRAS mutation status on outcomes metastatic colorectal cancer (mCRC) treated with anti-angiogenic agents is controversial. A total 4,066 mCRC patients from nine randomized contr...

参考文章(42)
Josep Tabernero, Heinz-Josef Lenz, Salvatore Siena, Alberto Sobrero, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Takayuki Yoshino, Richard M Goldberg, Daniel J Sargent, Andrea Wagner, Dirk Laurent, Michael Teufel, Michael Jeffers, Axel Grothey, Eric Van Cutsem, None, Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial The Lancet Oncology. ,vol. 16, pp. 937- 948 ,(2015) , 10.1016/S1470-2045(15)00138-2
Oriol Casanovas, Daniel J. Hicklin, Gabriele Bergers, Douglas Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell. ,vol. 8, pp. 299- 309 ,(2005) , 10.1016/J.CCR.2005.09.005
S. A. Forbes, N. Bindal, S. Bamford, C. Cole, C. Y. Kok, D. Beare, M. Jia, R. Shepherd, K. Leung, A. Menzies, J. W. Teague, P. J. Campbell, M. R. Stratton, P. A. Futreal, COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Research. ,vol. 39, pp. 945- 950 ,(2011) , 10.1093/NAR/GKQ929
Elias Zintzaras, John P. A. Ioannidis, Heterogeneity testing in meta-analysis of genome searches. Genetic Epidemiology. ,vol. 28, pp. 123- 137 ,(2005) , 10.1002/GEPI.20048
Luigi Rossi, Veltri, Angelo Zullo, Federica Zoratto, Longo, Mottolese, Diana Giannarelli, Ruco, Marchetti, Romiti, Barucca, Giannini, Silverio Tomao, Maria Colonna, Loredana Bianchi, Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. OncoTargets and Therapy. ,vol. 6, pp. 1761- 1769 ,(2013) , 10.2147/OTT.S43828
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019
Eduardo Díaz-Rubio, Auxiliadora Gómez-España, Bartomeu Massutí, Javier Sastre, Margarita Reboredo, José Luis Manzano, Fernando Rivera, Clara Montagut, Encarnación González, Manuel Benavides, Eugenio Marcuello, Andrés Cervantes, Purificación Martínez de Prado, Carlos Fernández-Martos, Antonio Arrivi, Inmaculada Bando, , , , Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study PLoS ONE. ,vol. 7, pp. e47345- ,(2012) , 10.1371/JOURNAL.PONE.0047345
Jean-Yves Douillard, Salvatore Siena, James Cassidy, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, György Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean-Luc Canon, Mark Rother, Kelly S Oliner, Michael Wolf, Jennifer Gansert, None, Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Journal of Clinical Oncology. ,vol. 28, pp. 4697- 4705 ,(2010) , 10.1200/JCO.2009.27.4860
William L. Ince, Adrian M. Jubb, Scott N. Holden, Eric B. Holmgren, Patti Tobin, Meera Sridhar, Herbert I. Hurwitz, Fairooz Kabbinavar, William F. Novotny, Kenneth J. Hillan, Hartmut Koeppen, Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab Journal of the National Cancer Institute. ,vol. 97, pp. 981- 989 ,(2005) , 10.1093/JNCI/DJI174
Marwan G. Fakih, Metastatic Colorectal Cancer: Current State and Future Directions Journal of Clinical Oncology. ,vol. 33, pp. 1809- 1824 ,(2015) , 10.1200/JCO.2014.59.7633